Since its establishment, Beijing Succeeder Technology Inc. has been engaged in the business for R&D, production and sales of instruments, reagents and consumables in the field of thrombosis and hemostasis in vitro diagnostics, providing medical institutions with coagulation, hemorheology, erythrocyte sedimentation rate and hematocrit, platelet aggregation and other automated instruments as well as original reagents and consumables, is a leading Chinese domestic manufacturer in the field of in vitro diagnosis of thrombosis and hemostasis.
Succeeder mainly adopts the business model of "autonomous R&D and production, sales-based production, production-based ordering, and distribution-oriented", and has formed a product system with autonomous core technology that integrates instruments, reagents and consumables, focusing on the development of coagulation testing products and hemorheology testing products, while continuously developing and innovating in product specialization, serialization and automation; and forming two major product series of blood coagulation and hemorheology, and series products with differentiated positioning, which can meet the demand of different levels of terminal medical institutions.
Succeeder has obtained 20 patents, 5 of which are invention patents; the self-developed thrombosis and hemostasis in vitro diagnostic products have obtained 21 medical device product registration certificates, including: 14 blood coagulation products, 5 hemorheology products, 1 item of erythrocyte sedimentation rate product, 1 item of platelet product.
Succeeder products cover the main testing items in the field of thrombosis and hemostasis in vitro diagnostics. Succeeder products are being installed in more than 8,000 domestic terminal medical institutions, including more than 800 tertiary hospitals, which can meet the main testing demand of the terminal medical institutions forin vitro diagnosis of thrombosis and hemostasis.
|Earnings Per Share||1.19||1.00||0.52|
|R&D expenditure as a % of operating revenue||6.04%||6.39%||7.70%|
|Total Owners' Equity||374.69||195.65||143.30|
|Net Cash Flows-Operating||60.94||58.15||32.68|
|Net Cash Flows-Investing||-5.10||-3.85||-2.54|
|Net Cash Flows-Financing||105.69||-4.04||-13.35|
|Name||No. of Shares Held (mn)||% of Shares Held|
|LYFE Denali Limited||2.27||2.78%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.